ClinicalTrials.gg
CompletedNCT03441555Updated Feb 1, 2022

A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia

A Phase 1 interventional study of Venetoclax and Alvocidib in Acute Myeloid Leukemia (AML), sponsored by AbbVie. Completed at 14 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-01.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2021, 5 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 202 studies testing venetoclax in Leukemia, Myeloid, Acute — 116 open to participants now, 144 under way, 21 of them phase 3. venetoclax · Leukemia, Myeloid, Acute.

Enrollment
142nd of 202
36 · median 57
Started
2018
with 10 others
Phase 1
38 of 202
16 open now
Registered
17th of 202
by date
Lead sponsor
15 of 202
AbbVie

Among the 202 studies testing venetoclax in Leukemia, Myeloid, Acute, this one is the 142nd largest by enrollment, is one of 11 that started in 2018, is one of 38 in phase 1, and was the 17th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

116 of the 202 studies testing venetoclax in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

111 more — sign in →

By country, each count listing its studies:

All 116 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 202 studies testing venetoclax in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

An open-label, dose-escalation study to assess the safety and pharmacokinetics (PK), to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of alvocidib with venetoclax when co-administered in participants with relapsed or refractory (R/R) acute myeloid leukemia (AML).

03

Conditions studied

  • Acute Myeloid Leukemia (AML)

Keywords

  • Cancer
  • Acute Myeloid Leukemia (AML)
  • relapsed Acute Myeloid Leukemia
  • refractory Acute Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have adequate coagulation, hematology, kidney, and liver function, per protocol.
  • Diagnosis of (R/R) acute myeloid leukemia (AML)
  • Meet the following disease activity criteria:
  • an established, confirmed diagnosis of AML by World Health Organization criteria excluding acute promyelocytic leukemia (APL)-M3; and
  • an (ECOG) performance status less than or equal to 2.
  • If male participant is sexually active, he must agree from day 1 through 6 months after the last dose of alvocidib or 90 days after the last dose of venetoclax, whichever is longer, to practice the protocol-specified protection.

Exclusion criteria

Exclusion Criteria:

  • History of any within the last 6 months except for those specified in this protocol and low-grade malignancies not requiring active treatment such as non-melanoma skin cancer, cervical intraepithelial neoplasia, or prostate cancer in situ.
  • Prior stem cell transplant within 6 months of study drug administration and no requirement for graft versus host therapy.
  • History of previous enrollment in Studies NCT02993523 or NCT03069352.
  • History of exposure to alvocidib or any other cyclin-dependent kinase 9 (CDK9) inhibitor.
  • History of Tumor Lysis Syndrome (TLS) due to previous exposure to venetoclax.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Venetoclax + Alvocidib

    Venetoclax administered orally once daily (QD) and Alvocidib administered as an intravenous infusion on Days 1, 2, and 3 for all 28-day treatment cycles. Different combinations of dose levels for venetoclax and alvocidib may be explored.

    Drug: Venetoclax · Drug: Alvocidib

Interventions

  • tablet, oral

    Also known as: ABT-199

  • Intravenous

    Also known as: Flavopiridol

06

What researchers measure

Primary outcomes

  1. Tmax of venetoclax

    Time to maximum plasma concentration (Tmax) of venetoclax

    Time frame: Approximately 32 days after first dose of study drug

  2. Clearance of Alvocidib

    Clearance (CL) of alvocidib

    Time frame: Approximately 32 days after first dose of study drug

  3. AUC0-∞ of Alvocidib

    Area under the plasma concentration-time curve from 0 to infinity (AUC0-∞) post-dose of alvocidib

    Time frame: Approximately 32 days after first dose of study drug

  4. Cmax of Venetoclax

    Maximum plasma concentration (Cmax) of venetoclax

    Time frame: Approximately 32 days after first dose of study drug

  5. Half-life (t1/2) of Alvocidib

    Half-life (t1/2) of alvocidib

    Time frame: Approximately 32 days after first dose of study drug

  6. AUC0-24 Post-dose of Venetoclax

    Area under the plasma concentration-time curve from 0 to 24 hours (AUC24) post-dose of venetoclax.

    Time frame: Approximately 32 days after first dose of study drug

  7. Cmax of Alvocidib

    Maximum plasma concentration (Cmax) of alvocidib.

    Time frame: Approximately 32 days after first dose of study drug

  8. AUCt Post-dose of Alvocidib

    Area under the plasma concentration-time curve from time zero to time t (AUCt) post-dose alvocidib.

    Time frame: Approximately 32 days after first dose of study drug

  9. Dose Escalation Phase: Recommended Phase 2 dose (RPTD) for Venetoclax and Alvocidib

    RPTD will be determined using available safety and pharmacokinetics data upon completion of the dose escalation phase.

    Time frame: Minimum first cycle of dosing (up to 28 days)

Secondary outcomes

  1. Complete Response (CR) Rate

    CR is defined as the proportion of participants with documented complete response (CR) based on International Working Group (IWG) criteria.

    Time frame: Up to approximately 8 months

  2. Combined CR Rate

    Combined CR rate is defined as CR + CRi (CR with incomplete blood count recovery) based on IWG criteria.

    Time frame: Up to approximately 8 months

  3. Objective Response Rate (ORR)

    ORR is defined as the proportion of participants with documented partial response (PR) or better based on IWG criteria.

    Time frame: Up to approximately 18 months

07

Study locations

14 sites
  • USC Norris Cancer Center /ID# 170844
    Los Angeles, California 90033, United States
  • UC Irvine /ID# 201093
    Orange, California 92868, United States
  • University of California, Davis Comprehensive Cancer Center /ID# 170799
    Sacramento, California 95817, United States
  • Sylvester Comprehensive Cancer /ID# 170761
    Miami, Florida 33136-1002, United States
  • Indiana Blood & Marrow Transpl /ID# 170793
    Indianapolis, Indiana 46237, United States
  • NYU Langone Medical Center /ID# 201559
    New York, New York 10016-6402, United States
  • Weill Cornell Medical College /ID# 170800
    New York, New York 10021, United States
  • Duke University Medical Center /ID# 170842
    Durham, North Carolina 27710-3000, United States
  • University of Pittsburgh Medic /ID# 170790
    Pittsburgh, Pennsylvania 15261, United States
  • Universitaetsklinikum Dresden /ID# 168636
    Dresden, 01307, Germany
  • Univ Klinik Eppendorf Hamburg /ID# 168633
    Hamburg, 20246, Germany
  • University Hospital of Wales /ID# 202302
    Cardiff, CF14 4EN, United Kingdom
  • Ninewells Hospital /ID# 202304
    Dundee, DD1 9SY, United Kingdom
  • St. James University Hospital /ID# 202303
    Leeds, LS9 7TF, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Jan 2021, 31 months.

Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's 31 months is below that.

Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2018
First posted
Feb 22, 2018
StartActual
May 30, 2018
Primary completionActual
Jan 25, 2021
CompletionActual
Jan 25, 2021
Last update
Feb 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03441555
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 22, 2018
Start date
May 30, 2018
Primary completion
Jan 25, 2021
Completion
Jan 25, 2021
Last update
Feb 1, 2022

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Venetoclax · Alvocidib

Start the discussion